Fierce Biotech March 13, 2024
With the FDA due to announce the approval of the first drug for metabolic dysfunction-associated steatohepatitis (MASH), Ionis Pharmaceuticals is raising its hand to showcase a phase 2 asset that has improved symptoms of the liver disease.
ION224 was tested in 160 patients with MASH, previously known as nonalcoholic steatohepatitis (NASH), over 51 weeks, according to a Wednesday press release. The main goal of the trial was liver histological improvement, measured by a standard scoring system for nonalcoholic fatty liver diseases like MASH.
The trial met the goal with both 120-mg and 90-mg doses, showing at least a two-point reduction in the metabolic dysfunction-associated steatotic liver disease (MASLD) disease activity score, which ranks symptoms such as fat buildup in the...
Today's Sponsors
Today's Sponsor